商贸零售 2025 年 05 月 18 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -29% -14% 0% 14% 29% 43% 2024-05 2024-09 2025-01 商贸零售 沪深300 相关研究报告 《关注零售行业中期投资策略：深挖 情 绪 消 费 景 气 赛 道 — 行 业 周 报 》 -2025.5.11 《悦享生活，深挖情绪消费景气赛道 —2025 年零售行业中期投资策略》 -2025.5.7 《零售企业经营持续承压，关注高景 气优质公司—行业周报》-2025.5.5 618 大促拉开帷幕，关注国货美妆表现 ——行业周报 | 黄泽鹏（分析师） | 陈思（联系人） | | --- | --- | | huangzepeng@kysec.cn | chensi@kysec.cn | | 证书编号：S0790519110001 | 证书编号：S0790124070031 | chensi@kysec.cn 证书编号：S0790124070031 投资主线三（化妆品）：关注具备差异化且能力持续迭代的优质国货美妆品牌， 重点推荐毛戈平、珀莱雅、上美股份、巨子生物、润本股份、丸美生物等 ...

Core Viewpoint - The article discusses the rebuttal by Huaxi Biological regarding the "outdated hyaluronic acid theory," claiming it is a narrative constructed by "restless capital" to divert attention from the necessary evolution of China's industry [1][4]. Group 1: Industry Context - Huaxi Biological argues that the rise of the "outdated hyaluronic acid theory" is a result of misleading narratives that have emerged in recent years, portraying hyaluronic acid as inferior to other substances [3][4]. - The company highlights that since 2022, the capital market has shifted its focus to the concept of recombinant collagen, which has been promoted through misleading comparative studies against the hyaluronic acid industry [3][4]. Group 2: Company Performance - Huaxi Biological has experienced a significant decline in net profit and stock price, with its market value dropping from over 140 billion yuan in 2021 to just 24.3 billion yuan currently [7]. - In contrast, competitors like Juzhi Biological, which went public in Hong Kong in 2022, have seen both their performance and stock price rise, with a current market value of 90.9 billion HKD [8]. - Another competitor, Jinbo Biological, listed on the Beijing Stock Exchange, has also seen its stock price double in recent months, reaching a market value of 42.5 billion yuan [9].

Core Insights - The healthcare industry is increasingly shifting towards consumer health and wellness sectors, with companies like Kelun Pharmaceutical entering the market to diversify their revenue streams amid declining traditional business performance [1][6][7] - The demand for stem cell therapy is rapidly growing in China, with some treatments costing up to 1 million yuan, leading to significant profits for service providers [1][3] - The aesthetic medicine sector is witnessing a surge in new registrations, with nearly 10,000 new medical beauty-related companies registered in early 2023, indicating a trend of traditional pharmaceutical companies pivoting to this area for survival [3][4] Company Strategies - Kelun Pharmaceutical's chairman has publicly stated the company's commitment to the health and wellness sector, highlighting the need for diversification due to intense competition in traditional medical fields [1][6] - Many companies are forming new entities or acquiring existing firms to enter the aesthetic medicine market, leveraging their traditional business strengths in production or marketing [3][4] - Companies like Chuaning Bio, previously focused on antibiotic intermediates, are now developing anti-aging products, although their contribution to revenue remains minimal at this stage [7] Financial Performance - Kelun Pharmaceutical reported a 30% decline in revenue and a 43% drop in net profit in Q1 2025, prompting a focus on anti-aging products [6] - Four环医药's aesthetic medicine segment generated approximately 323 million yuan in revenue in the first half of 2024, a 66.4% increase year-on-year, contributing significantly to the company's overall income [8] - Companies in the biological materials sector, such as Guanhao Bio, are also seeing growth in cell technology services, with related revenues exceeding 10% of total income [8] Regulatory Environment - Recent regulatory guidelines from the National Medical Products Administration are clarifying the direction for the commercialization of cell therapies, emphasizing the need for a robust management system to ensure safety [9] - The aesthetic medicine field is currently seen as a simpler entry point for regenerative medicine technologies, although many practices may not meet the rigorous standards of true regenerative medicine [5][9]

Core Viewpoint - *ST Suwu is facing scrutiny due to disclosure violations but is experiencing strong growth in its medical aesthetics business, which is expected to drive a turnaround in overall performance [1][2][3] Group 1: Financial Performance - In 2024, *ST Suwu achieved revenue of 1.599 billion yuan and gross profit of 773 million yuan, marking a year-on-year increase of 229 million yuan, or 42.12% [1] - The net profit attributable to shareholders reached 70.48 million yuan, a significant year-on-year growth of 197.97% [1] - In Q1 2025, the medical aesthetics segment generated revenue of 113 million yuan with a gross profit of 92.57 million yuan, while the pharmaceutical segment saw a revenue decline of 218.44 million yuan [2] Group 2: Business Strategy and Market Position - *ST Suwu has shifted its strategic focus from pharmaceutical business to medical aesthetics since early 2021, which has proven to be a forward-looking decision that opened new growth avenues [2] - The launch of the "Tongyan Needle" in January 2024 marked *ST Suwu's first entry into the medical aesthetics market, quickly gaining traction despite pricing controversies [2][3] - The company has established strong marketing efforts across various well-known medical aesthetics brands, enhancing its competitive position in the market [3]

Core Viewpoint - So-Young International Inc. reported a decline in total revenue for Q1 2025, with a significant growth in its light medical beauty chain business, indicating a strategic shift amidst increasing competition in the medical beauty industry [1][4]. Financial Performance - Total revenue for Q1 2025 was RMB 297 million, a year-on-year decrease of 6.6% [1]. - Net loss expanded from RMB 21.2 million in the same period last year to RMB 33.1 million [1]. - Revenue from the light medical beauty chain business surged by 551.4% to RMB 98.8 million, marking a record high for a single quarter [1]. Online Business Challenges - Revenue from information, reservation services, and others fell by 34.1% to RMB 143 million, previously RMB 217 million in Q1 2024 [4]. - Revenue from medical product sales and maintenance services decreased by 35.7% to RMB 55.6 million [4]. - Combined revenue from online services accounted for less than 67% of total revenue, down from 94% in the same period last year [4]. Industry Competition - The medical beauty industry is experiencing intensified competition, with major players like Alibaba Health and Meituan expanding their presence [1][4]. - New platforms such as Douyin and Xiaohongshu are reshaping traffic acquisition through live streaming and short videos, impacting traditional online models [5]. Strategic Initiatives - The company is focusing on vertical integration and business diversification to strengthen its competitive position [1]. - New-Young has launched its light medical beauty chain brand "So-Young Youth Clinic" and aims to improve service efficiency and reduce costs through centralized procurement [7][8]. - As of March 31, 2025, So-Young operates 23 medical beauty centers across nine major cities, with 18 centers achieving positive monthly cash flow [8]. Future Outlook - For Q2 2025, the company anticipates medical treatment service revenue to reach between RMB 120 million and RMB 140 million, representing a year-on-year growth of 337% to 410% [8]. - The company plans to continue expanding its offline medical beauty center business and improve operational efficiency [8].

Group 1 - The core viewpoint of the article highlights that New Oxygen Technology (SY.US) reported a revenue decline in Q1 2025, but still exceeded market expectations [1] - In Q1 2025, the company's revenue reached 40.97 million USD, a decrease of 6.6% year-on-year, while the GAAP diluted loss per share was 0.04 USD, slightly better than the market average expectation of a loss of 0.05 USD [1] - The decline in revenue was primarily due to a reduction in the number of medical beauty institutions on the subscription platform [1] Group 2 - The total transaction amount for medical beauty treatments facilitated by the platform in Q1 was 30.32 million RMB, down from 36.71 million RMB in the same period of 2024 [1] - The number of verified paid visits exceeded 45,500, showing a nearly ninefold increase compared to approximately 4,600 visits in the same period of 2024 [1] - The number of active users as of March 31, 2025, was over 75,700, compared to about 8,000 in the same period of 2024 [1] Group 3 - As of March 31, 2025, New Oxygen operates 23 medical beauty centers in nine major cities, with 18 centers achieving positive monthly operating cash flow [2] - For Q2 2025, the company expects medical beauty service revenue to be between 120 million RMB (approximately 16.5 million USD) and 140 million RMB (approximately 19.3 million USD), representing a year-on-year growth of 337.3% to 410.1% compared to the same period in 2024 [2]

Group 1 - The approval of Pyrocilin tablets (brand name: XuanYueNing) by XuanZhu Biotech marks a significant advancement in breast cancer treatment, being the only CDK4/6 inhibitor in China with both monotherapy and combination therapy indications [2] - Pyrocilin's unique mechanism targeting CDK2/4/6/9 allows for effective tumor cell proliferation blockade while reducing hematological toxicity, addressing the specific characteristics of Chinese breast cancer patients [3][4] - Clinical data shows that the median progression-free survival for second-line treatment patients is 14.7 months, with independent assessments showing up to 17.5 months, setting a new global record for similar therapies [4] Group 2 - XuanZhu Biotech's success in innovative drugs contributes to the overall strong performance of Sihuan Pharmaceutical, with a notable increase in revenue from both medical aesthetics and innovative drugs [5] - The medical aesthetics segment saw a revenue increase of 65.4% to 744 million yuan, supported by a dual strategy of self-research and product introduction [6] - Revenue from innovative drugs surged by 388.1% to 57.6 million yuan, driven by the approval of new drugs and a robust pipeline nearing commercialization [7] Group 3 - Sihuan Pharmaceutical maintains high R&D investment, with approximately 474 million yuan spent in the year, despite an 18% decrease due to multiple products completing Phase III trials [9] - The company has a strong cash position, with net cash flow from operating activities at 244 million yuan and cash reserves nearing 4 billion yuan, providing ample support for ongoing clinical trials [9] Group 4 - The Hong Kong stock market is experiencing a structural recovery, with the Hang Seng Healthcare Index rising over 30% this year, highlighting the potential for undervalued pharmaceutical stocks [10] - Sihuan Pharmaceutical is identified as a key player with significant growth potential, as its market capitalization is approximately 5.7 billion yuan, nearly equal to its cash and liquid assets [10] - The company's dual focus on medical aesthetics and innovative drugs positions it well for future growth, with a strong likelihood of market revaluation [10][11]

Core Viewpoint - The medical beauty industry is experiencing a significant performance divergence among listed companies, driven by a shift from hyaluronic acid to collagen products, indicating a potential restructuring of industry value logic [1][3]. Group 1: Performance Analysis - In 2024, the performance of upstream medical beauty companies showed significant divergence, with companies like Juzi Biological and Jinbo Biological leading with high growth rates, while major hyaluronic acid players like Aimeike, Huaxi Biological, and Haohai Biological faced pressure [2][3]. - Aimeike's revenue growth slowed to 5.45%, the lowest since its listing, while Huaxi Biological's revenue declined by 11.61% and net profit dropped by 70.59% [3][5]. - Juzi Biological achieved revenue of 5.539 billion, a year-on-year increase of 57.2%, and a net profit of 2.062 billion, up 42.4% [5][7]. Group 2: Market Trends - The market for recombinant collagen products in China is projected to grow from 18.5 billion in 2022 to 108.3 billion by 2027, with a compound annual growth rate of 42.4% [7]. - Companies are increasingly entering the collagen market, including Aimeike and Huaxi Biological, which are exploring new opportunities in this segment [7][8]. - Huaxi Biological is developing proprietary recombinant human collagen products that have entered clinical trials, indicating a strategic shift towards innovative product development [7].

Core Viewpoint - The concept of "involution" in the mother and baby industry does not equate to growth; instead, the focus should be on achieving tangible growth through innovative strategies and collaboration [1]. Group 1: Event Overview - The NBM Mother and Baby & Nutrition Health Innovation Exhibition took place on May 14-15, featuring a theme of "New Technology, New Products, New Buyers" [1]. - The exhibition included 15 high-end forums and industry summits, attracting over 100 experts and industry leaders from various fields [1]. - The event saw significant online engagement, with over 500,000 viewers participating in live broadcasts [1]. Group 2: Key Discussions and Insights - The "熊小婴·大健康专业论坛" focused on achieving differentiation in a saturated market through a "medical + content + supply chain" ecosystem [4][5]. - The importance of building a "scientific trust chain" was emphasized, highlighting the need for scientific product development, clinical validation, and professional market communication [7]. - The "悦己经济" forum discussed the integration of the medical beauty and mother-baby industries, driven by young parents' desire to maintain personal value while caring for children [13]. Group 3: Marketing Strategies - The marketing strategies discussed included a four-step method for content creation that simplifies complex medical knowledge for consumers [9]. - The need for a comprehensive content marketing system was highlighted, focusing on emotional and value-based connections with consumers [16]. - The role of AI technology and social media platforms like Douyin and video accounts in driving long-term growth for the mother and baby e-commerce sector was explored [17][19]. Group 4: Market Trends and Consumer Insights - Data analysis presented insights into the evolving consumer demands and market structure within the mother and baby sector, indicating a shift towards personalized and high-end products [21]. - The integration of professional resources and cross-industry innovation is seen as a new driving force for growth in the mother and baby industry [21].

Core Viewpoint - *ST Suwu's stock price fell sharply due to the chairman's investigation for information disclosure violations, raising concerns about the company's future and potential delisting risks [1][3]. Group 1: Company Investigation and Financial Health - On May 14, *ST Suwu announced that its chairman, Qian Qunshan, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected information disclosure violations [1]. - The company has been under investigation since February 27 for similar allegations, and it has not yet received a conclusive opinion from the CSRC [3]. - The accounting firm, Zhongxing Caiguanghua, issued an audit report for 2024 stating it could not express an opinion due to significant overdue receivables totaling 1.062 billion yuan, with 1.027 billion yuan overdue [3]. - The company also reported that 769 million yuan of its funds were occupied by related parties, increasing the risk of delisting [3]. Group 2: Business Strategy and Performance - Since its establishment in 1994, *ST Suwu has diversified into pharmaceuticals, chemicals, and real estate, with a recent focus on the medical aesthetics sector [4]. - The company achieved profitability after two years of losses, with revenues of 2.026 billion yuan in 2022 and 2.240 billion yuan in 2023, and a projected net profit of 55 to 80 million yuan for 2024, largely due to sales of the "Tian Yan Needle" [4]. - The sales revenue from the "Tian Yan Needle" reached 195 million yuan, with a gross margin of 82.89%, contributing significantly to the company's turnaround [4]. Group 3: Market Competition and Challenges - Despite the turnaround, *ST Suwu faces significant cash flow pressure, with cash reserves dropping from 1.152 billion yuan in 2024 to 168 million yuan in Q1 2025, against short-term borrowings of 1.304 billion yuan [5]. - The medical aesthetics market is highly competitive, with eight similar products already approved in China, posing a risk to *ST Suwu's market position [5]. - The exclusive sales rights for the "Tian Yan Needle" will last until 2032, but competition from other companies, including a major player acquiring the parent company of the product, could impact future sales [5][6].